senescence, causing quiescence instead [27] . p53 affects autophagy and metabolic pathways not only via inhibition of mTOR but also probably independently from mTOR [22, [28] [29] [30] [31] [32] [33] [34] [35] . We use the term mTORcentric network to encompass not only upstream and downstream but also parallel and TOR-like pathways [36] . p53 can both induce and suppress cellular senescence [37] . First, p53 causes cell cycle arrest, a prerequisite of senescence. Second, p53 inhibits mTOR-centric network and this can prevent senescence, causing quiescence instead. In cell lines with overactivated mTOR, p53 causes senescence [37] . Similarly, "weak" p53 that is not able to inhibit mTOR causes senescence simply by arresting the cell cycle [38] . In other words, p53 causes senescence passively by failing to suppress the senescence program (which in part depends on mTOR), while still causing cell cycle arrest. This model suggests that cell cycle arrest is the only mechanism of how p53 causes senescence. This predicts that induction of p53 will not cause senescence in quiescent cells, since in quiescent cells mTOR is already inhibited. Here we tested this hypothesis.
RESULTS

Induction of p53 by etoposide in quiescent cells has little consequence
As we recently demonstrated, unlike nutlin-3a (an Mdm-2 antagonist), low concentrations of doxorubicin (DOX), a DNA damaging drug (DDD), caused senescent morphology in WI-38t cells [38] . Nutlin-3a causes cell cycle arrest solely by inducing p53, which in turn can inhibit the mTOR pathway. DOX causes cell cycle arrest at concentrations that induce p53 not high enough to inhibit mTOR. Therefore, DOX caused senescence as was determined by senescent morphology [38] . However, DOX is not washable and we could not check whether the condition was irreversible. Here we used etoposide, a DDD that could be washed out. We treated WI-38t cells with either etoposide or nutlin-3a. After 4 days, cells were washed and re-plated without drugs ( Figure 1A ). After 6 days, the number of nutlintreated cells increased ~26 fold, whereas etoposidetreated cells could not proliferate ( Figure 1A ). In parallel, cells were treated with nutlin-3a and etoposide in the presence of rapamycin ( Figure 1B ). Rapamycin were plated at 10000 cells/well in 24-well plates, and the next day were either left untreated (A) or pretreated with 10 nM Rapamycin (B). The next day, cells were treated with either 2.5 µM nutlin-3a or 1 µg/ml etoposide or left untreated. After 4 days, cells were trypsinized and 10% of cells were plated in fresh drug-free medium (blue bars). 6 days later cells were counted (red bars). In C the results for etoposide treatment (Et) with or without rapamycin (R) pretreatment are shown in the same scale. (D) Cells were lysed after 24 hr treatment with etoposide (E), rapamycin (R), or both (R+E) and immunoblot was performed.
www.impactaging.com partially sustained the proliferative potential (PP) in etoposide-treated cells. Direct comparison of the proliferative potential of WI-38t cells treated with etoposide in the absence or presence of rapamycin is shown in Figure 1C . Etoposide did not inhibit mTOR and inhibition of mTOR by rapamycin-pretreatment ( Figure 1D ) favored quiescence over senescence ( Figure  1C ).
We further investigated effects of etoposide in cells treated by either rapamycin or serum starvation as depicted in Figure 2 . Exposure of WI-38t cells to either rapamycin or serum starvation resulted in a lean cellular morphology, a characteristic of quiescence ( Figure 3A , left column). Treatment of proliferating WI-38t cells with etoposide caused senescent morphology ( Figure  3A , top right panel). Senescent morphology was partially preventable by rapamycin and serumstarvation: most cells were lean and thin ( Figure 3A , right column). Rapamycin did not inhibit proliferation completely but rather slowed it down ( Figure 3B ). In were plated at 5000/well in 12 well plates, and the next day either treated with 10 nM rapamycin in complete medium (R), or placed in serum-free medium (no serum or 0), or left in complete medium (control). The next day, 1 µg/ml etoposide (Et) was added, as indicated. A. After 4 days, cells were stained for beta-Gal and microphotographed (bar -50 micron) B. After 4 days, cells were counted: control (C), rapamycin (R), no serum (0). C. Proliferative potential. In replicate plates, cells were washed and incubated in complete, drug-free medium for 6 days and then counted (black bars). Note: red bars correspond to red bars in panel B. Fold (f) increase in a cell number after drug removal. D. Immunoblot. Cells were plated in 6 well plates. The next day, cells were treated with 1 µg/ml etoposide (Et) for 24 hrs: control -C, rapamycin -R, no serum -0.
www.impactaging.com agreement with similar experiment ( Figure 1C ), rapamycin partially prevented loss of proliferative potential caused by etoposide ( Figure 3C ). Serum starvation preserved proliferative potential (PP) in etoposide-treated cells ( Figure 3C ). Etoposide induced p53 in serum-starved cells even stronger than in control (proliferating) cells ( Figure 3D ). So the failure to initiate senescence could not be explained by lack of p53 induction.
We next investigated etoposide-induced senescence in normal retinal pigment epithelial (RPE) cells. Etoposide caused senescent morphology in RPE cells ( Figure 4A ). Pretreatment with rapamycin and serum-starvation partially prevented senescent morphology caused by etoposide. The senescent morphology was associated with permanent loss of proliferative potential: cells could not resume proliferation, when etoposide was removed ( Figure 4B , C). In rapamycin-pretreated cells and, especially, in serum-starved cells, etoposideinduced arrest was partially reversible. Both rapamycin and serum starvation inactivated the mTOR pathway, as measured by a decrease of S6 phosphorylation ( Figure  4D ), but did not prevent p53 and p21 induction by etoposide ( Figure 4D ). Noteworthy, rapamycin activated Akt ( Figure 4D ). Serum-starvation was more effective than rapamycin in preventing etoposide-induced senescence. This suggests that mTOR pathway is not the only pro-senescent pathway and that is why rapamycin was less effective than serum-starvation in preventing senescence. As an example, compared with rapamycin, serum starvation was a more potent inducer of autophagy as judged by accumulation of LC3B-II ( Figure 4D ). A-C. RPE cells were plated at 5000/well in 12 well plates, and the next day either treated with 10 nM rapamycin in complete medium (R), or placed in serum-free medium (no serum or 0), or left in complete medium (control). The next day, 0.5 µg/ml etoposide (Et) was added, as indicated. A. After 4 days, cells were stained for beta-Gal and micro-photographed (bar -50 micron) B. After 4 days, cells were counted: control (C), rapamycin (R), no serum (0). C. Proliferative potential. In replicate plates, cells were washed and incubated in complete, drug-free medium for 6 days and then counted (black bars). Note: red bars corre-spond to red bars in panel B. Fold (f) increase in a cell number after drug removal. D. Immunoblot. Cells were plated in 6 well plates. The next day, cells were treated with 0.5 µg/ml etoposide (Et) for 24 hrs: control -C, rapamycin -R, no serum -0.
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Effects of higher concentrations of etoposide
We next investigated whether higher etoposide concentrations and durations of treatment convert quiescence into senescence. Like 0.5 µg/ml, 10 µg/ml etoposide did not inhibit mTOR ( Figure 5A ) and thus caused senescent morphology and loss of proliferative potential ( Figure 5B, C) . In WI-38t cells, rapamycin pretreatment partially preserved proliferative potential in both concentrations of etoposide ( Figure 5B ). Serumstarvation was insignificantly effective probably due to its toxicity during a 6-day treatment. At the time of cell count ( Figure 5B ), WI-38t cells treated with etoposide alone retained senescent morphology, whereas co-treatment with rapamycin and serum starvation (no serum) abrogated senescent morphology ( Figure 5C ). In RPE cells, which are more sensitive to etoposide, rapamycin and serum-starvation significantly preserved proliferative potential of cells treated with 0.5 µg/ml but not 10 µg/ml etoposide ( Figure 5B ). Still these cotreatments abolished senescent morphology otherwise caused by 10 µg/ml etoposide ( Figure 5C ).
Conversion from quiescence to senescence
Using the schema depicted in Figure 6 , we next investigated the effect of re-addition of serum to cells treated with DDD in serum-free medium without removal of the drug. In WI-38t cells, addition of serum caused phosphorylation of Akt, Erk and S6 and also induced cyclins D1 and E ( Figure 7A A. Immunoblot: WI-38t and RPE cells were treated with 0.5 µg/ml and 10 µg/ml etoposide (Et) or left untreated (-). The next day, cells were lysed and immunoblot was performed. B-C: WI-38t and RPE cells were plated at 25000/well in 12 well plates, the next day cells were either pretreated with 10 nM rapamycin (Rapa), placed in serum free medium (no serum) or left in complete medium with 10% serum (control). The next day, 0.5 µg/ml and 10 µg/ml etoposide (Et) was added: in complete medium (control) or with 10 nM Rapamycin (Rapa) or in serum free medium (no serum). After 5 days, cells were washed and cultured in fresh, drug free medium for 11 days and then trypsinized and counted. (in panel C): Before trypsinization, cells treated with 10 µg/ml etoposide (under three conditions: control, Rapa and no serum) were microphotographed.
morphology ( Figure 7B ). Thus senescence was characterized by activated mTOR-centric pathways and elevated cyclins D1 and E. Rapamycin prevented S6 phosphorylation (downstream of mTOR), but not phosphorylation of Akt and Erk, which are upstream of mTOR. Simultaneously it diminished senescent morphology, so that most cells remained lean ( Figure 7B ). Similar results were obtained when cells were blocked with doxorubicin ( Figure 8 ). Re-addition of serum caused senescence instead of proliferation (Figure 8) . Similarly, in etoposide-or doxorubicin-blocked RPE cells, serum stimulation caused activation of mTOR ( Figure 9A ) and senescent morphology (Figure 9 and 10).
Conversion between nutlin-induced quiescence and senescence in cancer cells
Whereas nutlin-3a causes quiescence in WI-38t and RPE cells, it causes senescence in some cancer cell lines with high mTOR activity. For example, nutlin-3a did not block phosphorylation of S6 and caused senescence in Mel-10 cells. As we have shown, senescence was preventable by rapamycin [37] . The advantage of the nutlin-based model is that nutlin-3a does not cause DNA damage. Although serum-starvation did not cause genuine quiescence in cancer cells, serum starvation still prevented typical senescent morphology during treatment with nutlin-3a. Mel-10 cells remained slim, when were treated with nutlin-3a in serum-free medium. The cells were beta-gal positive ( Figure  11A ), because serum starvation alone may cause betagal staining. Serum-starvation by itself did not decrease p-S6 by day 1 ( Figure 11B ), there was a noticeable decrease in phosphorylation of S6 in nutlintreated cells maintained in a serum-free medium ( Figure 11B ). Re-addition of serum converted lean morphology into typical senescent phenotype ( Figure   11C ). In MCF-7 cells, nutlin-3a also induced senescent morphology ( Figure 12A ) and in agreement did not inhibit S6 phosphorylation ( Figure 12C ). However, non-proliferating senescent cells co-existed with still proliferating cells, which formed colonies with nonsenescent morphology. (Notably, higher concentration of nutlin-3a caused cell death, data not shown). Serum starvation slowed down proliferation of MCF-7 cells (Figure. 12B ). Induction of p53 in serum-starved cells by nulin-3a caused rapid and massive cell death ( Figure 12A, lower panel) . Nutlin-3a induced especially high levels of p53 in serum-starved cells (Fig 12C) . This can explain both inhibition of p-S6 and cell death, according to the recent model [38] .
We also utilized rapamycin, which abrogated S6 phosphorylation, while did not prevent p53 induction by nutlin-3a ( Figure 12C ). In rapamycin-pretreated MCF-7 cells, nutlin-3a did not cause morphological senescence ( Figure 12A ). In other words, senescence was converted into quiescence. Unlike senescent cells, quiescent cells were not morphologically distinct from proliferating cells. So after treatment with nutlin-3a plus rapamycin, there could be a mixture of proliferating and quiescent cells. Therefore, in order to link the morphology to the proliferative potential of arrested cells, we needed to selectively eliminate proliferating cells first. This task unexpectedly merged with our investigation of drug combinations that could protect cells with wt p53 from the toxicity of chemotherapy. Using this approach, we demonstrated that rapamycin converted nutlin-induced senescence into quiescence in MCF-7 cells (MS in preparation).
DISCUSSION
In this study we tested the idea that while causing senescence in proliferating cells, DNA damaging drugs and induced p53 will not cause senescence in quiescent cells. To this point we 1) induced quiescence prior to p53 induction and 2) used p53-inducing agents that could be washed out to observe whether treated cells would retain proliferative potential. Etoposide, which causes DNA damage, was used for normal cells and nutlin-3a, which induces p53 without DNA damage, was used for cancer cells. Both agents could be washed out to check the reversibility of arrest. We used these drugs at concentrations that caused senescence in proliferating cells. When applied to serum-starved and rapamycin-treated cells, p53-inducing drugs did not completely convert quiescence into senescence. Cells retained mostly quiescent morphology and some degree of proliferative potential, resuming proliferation in fresh (drug-free, serum-containing) medium.
Although not causing senescence, induction of p53 in quiescent cells 'locked' the cell cycle. In quiescence caused by serum starvation, the cell cycle is inactive (due to low levels of cyclins) but not blocked. In quiescent cells, induction of p53 blocks the cell cycle (in addition to its deactivation). Re-addition of serum to such blocked (locked) quiescent cells did not cause proliferation. Instead it caused senescence. This is in agreement with the notion that senescence is a form of growth, a continuation of growth, when proliferation is impossible [18, 39] .
Thus, induction of p53 by different agents (including DNA damaging drugs) did not cause senescence in serum-starved and rapamycin-treated cells. It is less clear whether DNA damaging agents induced identical DNA damage in all conditions. One potential problem is that DNA damaging drugs may induce a lesser DNA damage in quiescent cells. However, first, we utilized etoposide, which was reported to induce damage in all phases of the cell cycle [40] [41] [42] [43] [44] [45] . Second, etoposide induced the same levels of p53 in proliferating, serumstarved and rapamycin-treated cells. (Note: Although p53 could be induced independently from DNA damage, this has not been described for etoposide. DNA damage response such as gamma-H2AX is also not absolutely reliable marker because it may occur in the absence of DNA damage in senescent cells [46, 47] ). Therefore, direct measurement of DNA damage by comet assay is warranted. 0.5 µg/ml etoposide did not induce obvious comets both in control and serum-free conditions. 10 µg/ml etoposide induced comets in serum-starved cells (Supplemental Figure 1) . We conclude that, in agreement with literature data, etoposide induces DNA damage in serum-starved cells (some of which may still cycling at the moment of etoposide treatment) but more detailed measurements are needed for quantitative results. Third, simultaneous serum-withdrawal and addition of doxorubicin also suppressed senescence and this effect cannot be explained by cell cycle arrest caused by serum withdrawal. Fourth, DNA damaging drugs were even more cytotoxic in serum free-medium, indicating damage. Thus, it is not that etoposide is less cytotoxic in serumfree medium but rather that cells retain lean morphology and prolifertative potential (the ability to proliferate in fresh medium). At high concentrations, damaging agents and p53 can induce cell death rather than senescence in serum-starved cells. Yet, according to our preliminary data, if drugs are removed before death occurs, serum-restimulated survived cells can become senescent. TOR-independent latent senescence caused by high levels of DNA damage is an intriguing topic for further investigations.
In conclusion, quiescence is characterized by inactive mTOR both in cell culture [18, 19] and in the organism A-B. MCF7 cells were plated at 5000 or 10000/well in 12 well plates, allowed to attach and then were either pretreated with 500 nM rapamycin (R), placed in serum free medium or left untreated in complete medium (control). The next day, 5µM nutlin-3a was added. After 5 days, cells were stained for beta-Gal and microphotographed (bars -50 micron) (A). (B) In replicate plate, cells were counted. C. MCF7 cells were treated as indicated for 24 hr, and immunoblot was performed.
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MATERIALS AND METHODS
Cell lines and reagents. WI-38-Tert, WI-38 fibroblasts immortalized, and RPE, retinal pigment epithelial cells were described previously [18] . RPE cells were cultured in MEM with 10% FBS, WI-38-tert cells were cultured in low glucose DMEM with 10%FBS. MEL-10, melanoma cell line, and MCF-7, breast cancer cell line, were cultured in DMEM (plus pyruvate) with 10% FBS. Rapamycin was obtained from LC Laboratories, MA, USA. Nutlin-3a, etoposide and doxorubicin were from Sigma-Aldrich.
Immunoblot analysis. Whole cell lysates were prepared using boiling lysis buffer (1%SDS, 10 mM Tris.HCl, pH 74.). Equal amounts of proteins were separated on 10% or gradient polyacrylamide gels and transferred to nitrocellulose membranes. The following antibodies were used: mouse anti-p53 (Ab-6) from Oncogene, mouse anti-p21 from BD Biosciences; rabbit anti-actin from Sigma-Aldrich; rabbit anti-phospho-S6 (Ser235/ 236), mouse anti-S6, rabbit anti-phospho AKT, rabbit anti-LC3B, anti-phospho ERK from Cell Signaling; anti-cyclins D1 and E from Santa Cruz Biotechnology. Secondary goat anti-rabbit and goat anti-mouse HRP conjugated antibodies were from Chemicon and BioRad, respectively. Signals were visualized using ECL chemilumenescence kit from Pierce.
SA-β-Gal staining. Beta-Gal staining was performed using Senescence-galactosidase staining kit (Cell Signaling Technology) according to manufacturer's protocol. Cells were incubated at 37 o C until beta-gal staining becomes visible. Development of color was detected under light microscope.
Neutral comet assay was performed according to manufacturer's protocol.
Proliferative potential was determined as described in detail in Figure legends. 
